ABL1 and acute lymphoblastic leukemia: The working group recommends that molecular MRD testing for Ph-positive ALL should be centralized in a laboratory using reverse transcription real-time quantitative PCR (RT-qPCR) for both the p210 and p190 BCR-ABL1 transcripts [29,51].